Fri, Nov 20, 2026中文About
Filings today 284 / Covered 15
Source: TDnet timely disclosures
Updated 11/20 20:30M&A / TOB 20 Guidance 7 Buybacks 11 Dividends 4 Capital 12 Earnings 16 People 3

Toyobo cuts FY net profit forecast to ¥4.0 billion on ¥6.5 billion impairment

Mon, Nov 09, 2026 13:00 JST Toyobo Co., Ltd. (3101.T) Chemicals 中文

Toyobo Co., Ltd. (3101) cut its full-year net profit forecast by 42.9% to ¥4.0 billion after booking a ¥6.5 billion impairment loss on its pharmaceutical contract manufacturing business, while raising its operating profit outlook to ¥27.0 billion from ¥23.0 billion.

Impairment loss¥6.5 billion
Revised FY net profit forecast¥4.0 billion (from ¥7.0 billion)
Revised FY operating profit forecast¥27.0 billion (from ¥23.0 billion)
First-half operating profit¥16.259 billion

The company said contract volumes at the pharmaceutical unit fell as competing products emerged, and after reviewing its business plan it wrote the unit's assets down to their recoverable value in the second quarter. Solid sales of release film for ceramic capacitors and Cosmoshine SRF polarizer protective film lifted the sales and profit outlook.

ItemPreviousRevised
Net sales¥435.0 billion¥440.0 billion
Operating profit¥23.0 billion¥27.0 billion
Ordinary profit¥18.5 billion¥22.1 billion
Net profit¥7.0 billion¥4.0 billion

For the April-September first half, net sales rose 7.1% to ¥218.459 billion and operating profit climbed 37.9% to ¥16.259 billion, while net profit fell 40.6% to ¥3.405 billion. The life science segment posted an operating loss of ¥1.6 billion, versus a ¥100 million profit a year earlier. The year-end dividend forecast was kept at ¥40 per share.

Separately, Toyobo booked ¥500 million in retirement-related costs tied to the suspension of El Salvador subsidiary INDUSTRIAS UNIDAS, S.A. (IUSA), and a ¥1.3 billion gain on the first handover of IUSA fixed assets. The impact on the full-year forecast is still under review.

Next steps: Toyobo plans to file its semiannual report on Nov. 11, 2026. Further IUSA suspension costs are expected from the third quarter, and the second asset handover is scheduled for May 2027, with the gain to be booked in the first quarter of the fiscal year ending March 2028.


Original filings
Related